PharmaJet will deliver two presentations on October 27 focusing on current and future applications of their needle-free ...

Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...

Clinical Director of the National Institute of Drug Abuse Dr. Lorenzo Leggio, said GLP-1 drugs' effect on the brain can help ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...

Chances are, you may know a family living with food allergies. Food allergies are more prevalent than many realize, ...

Understand the differences between hereditary and histamine-mediated angioedema, including their symptoms, causes, and ...

Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...

The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to ...

TOKYO/CAMBRIDGE - Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a robust gross profit margin of 76.3% and strong financial health according to InvestingPro ...